FDA advisory panel endorses Grail's Galleri multi-cancer blood test
An FDA advisory committee has concluded that the benefits of Galleri, a circulating-tumour-DNA screening test covering multiple cancer types, outweigh its risks.
An FDA advisory panel has voted to endorse Galleri, a liquid-biopsy blood test developed by the biotech company Grail, designed to detect signals from more than 50 cancer types from a single blood draw. The committee's conclusion — that the test's benefits outweigh its risks — marks a significant step towards potential regulatory approval, though a formal FDA decision would follow separately.
Galleri detects cell-free DNA shed by tumours into the bloodstream and uses methylation patterns to infer both the presence of a cancer signal and the likely tissue of origin. The test has been available in the United States on a commercial basis since 2021 as a laboratory-developed test, but an FDA advisory panel endorsement brings it closer to a regulated approval pathway.
Liquid-biopsy approaches such as Galleri have attracted considerable research and policy interest because they offer the potential to detect cancers at earlier stages and across multiple sites without invasive procedures. Cancer Research UK published a parallel analysis noting that, while the technology holds promise for improving detection and treatment monitoring, broader deployment will require robust evidence on clinical utility, equitable access, and integration into established care pathways.
The advisory panel's endorsement does not constitute FDA approval; the agency is not bound by its advisory committees' recommendations, though it typically gives them substantial weight. Researchers and clinicians will be watching for the agency's final decision and for further data on performance across diverse populations.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Researchers and regulators in the United States have been looking at a blood test called Galleri, made by a company called Grail. The test works by looking for tiny fragments of DNA that cancer cells shed into the blood — a technique known as liquid biopsy. An expert advisory panel set up by the US Food and Drug Administration (FDA) has said it believes the benefits of Galleri outweigh the risks, which is an important step in the process of deciding whether to formally approve the test.
This does not mean the test is approved yet — the FDA makes its own final decision, usually sometime after the advisory panel reports. Researchers note that more evidence is still needed on how well the test works in different groups of people, and how its results would fit into existing cancer care.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-09-23STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
-
Cancer Research UK · 2026-09-24What's next for liquid biopsy in cancer diagnosis and treatment?